表紙
市場調査レポート

Camurus AB : 製品パイプライン分析

Camurus AB - Product Pipeline Review - 2015

発行 Global Markets Direct 商品コード 226302
出版日 ページ情報 英文 24 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.50円で換算しております。
Back to Top
Camurus AB : 製品パイプライン分析 Camurus AB - Product Pipeline Review - 2015
出版日: 2015年09月09日 ページ情報: 英文 24 Pages
概要

Camurus AB 研究開発指向型の製薬会社で、高付加価値を持つ治療法向けにナノスケールの薬物送達システムを開発しています。このようなナノスケールによって、ペプチドや蛋白質、不溶性の小分子といった、これまで難しかった薬剤化合物も幅広く送達できようになります。例えば、前立腺がん、代謝障害、糖尿病、歯根膜炎、口腔粘膜炎、成長ホルモン分泌不全、薬物依存症候群などに有効な製品を開発製造しています。

当レポートでは、Camurus AB における治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

Camurus ABの基本情報

Camurus ABの概要

  • 主要情報
  • 企業情報

Camurus AB:R&Dの概要

  • 主な治療範囲

Camurus AB:パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品
  • アウトライセンス製品
    • アウトライセンス製品/併用療法モダリティ

Camurus AB:パイプライン製品の概況

  • 治験段階にあるパイプライン製品
    • 第II相にある製品/併用療法モダリティ
    • 第I相にある製品/併用療法モダリティ

Camurus AB:薬剤プロファイル

  • buprenorphine hydrochloride
  • leuprolide acetate
  • CAM-2048

Camurus AB:パイプライン分析

  • 標的別
  • 投与経路別
  • 分子タイプ別
  • 作用機序別

Camurus AB:最近のパイプライン動向

Camurus AB:本社と子会社の所在地

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC07568CDB

Summary

Global Markets Direct's, 'Camurus AB - Product Pipeline Review - 2015', provides an overview of the Camurus AB's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Camurus AB's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Camurus AB including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Camurus AB's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Camurus AB's pipeline products

Reasons to buy

  • Evaluate Camurus AB's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Camurus AB in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Camurus AB's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Camurus AB and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Camurus AB
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Camurus AB and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Camurus AB Snapshot
    • Camurus AB Overview
    • Key Information
    • Key Facts
  • Camurus AB - Research and Development Overview
    • Key Therapeutic Areas
  • Camurus AB - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • Camurus AB - Pipeline Products Glance
    • Camurus AB - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
  • Camurus AB - Drug Profiles
    • buprenorphine hydrochloride
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • leuprolide acetate
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CAM-2048
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Camurus AB - Pipeline Analysis
    • Camurus AB - Pipeline Products by Target
    • Camurus AB - Pipeline Products by Route of Administration
    • Camurus AB - Pipeline Products by Molecule Type
    • Camurus AB - Pipeline Products by Mechanism of Action
  • Camurus AB - Recent Pipeline Updates
  • Camurus AB - Dormant Projects
  • Camurus AB - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Camurus AB, Key Information
  • Camurus AB, Key Facts
  • Camurus AB - Pipeline by Indication, 2015
  • Camurus AB - Pipeline by Stage of Development, 2015
  • Camurus AB - Monotherapy Products in Pipeline, 2015
  • Camurus AB - Out-Licensed Products in Pipeline, 2015
  • Camurus AB - Out-Licensed Products/ Combination Treatment Modalities, 2015
  • Camurus AB - Phase II, 2015
  • Camurus AB - Phase I, 2015
  • Camurus AB - Pipeline by Target, 2015
  • Camurus AB - Pipeline by Route of Administration, 2015
  • Camurus AB - Pipeline by Molecule Type, 2015
  • Camurus AB - Pipeline Products by Mechanism of Action, 2015
  • Camurus AB - Recent Pipeline Updates, 2015
  • Camurus AB - Dormant Developmental Projects,2015
  • Camurus AB, Other Locations

List of Figures

  • Camurus AB - Pipeline by Top 10 Indication, 2015
  • Camurus AB - Pipeline by Stage of Development, 2015
  • Camurus AB - Monotherapy Products in Pipeline, 2015
  • Camurus AB - Pipeline by Top 10 Target, 2015
  • Camurus AB - Pipeline by Top 10 Molecule Type, 2015
  • Camurus AB - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top